Apostolos Achimastos, Theodoros Alexandrides, Dimitrios Alexopoulos, Vasilios Athyros, Alexandra Bargiota, Eleni Bilianou, Christina Chrysochoou, Evridiki Drogari, Moses Elisaf, Emanouel Ganotakis, Ioannis Goudevenos, Ioannis Ioannidis, Genovefa Kolovou, Vasilios Kotsis, Ioannis Lekakis, Evangelos Liberopoulos, Andreas Melidonis, Vasilios Nikolaou, George Ntaios, Nikolaos Papanas, Stavros Pappas, Christos Pitsavos, Loukianos Rallidis, Dimitrios Richter, Ioannis Skoumas, Nicolaos Tentolouris, Dimitrios Tousoulis, Alexandros Tselepis, KonstantinosTsioufis, Dimitrios Tziakas, Konstantinos Tziomalos, Panagiotis Vardas, Charalabos Vlachopoulos, Dimitrios Vlahakos
Two proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, evolocumab and alirocumab, have recently been approved by both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of hypercholesterolemia. These fully human monoclonal antibodies selectively block PCSK9, thus permitting the low-density lipoprotein (LDL) receptor to effectively recycle to the surface of liver cells. The administration of these antibodies leads to robust LDL …